Todas las fotos(1)

Key Documents

View All Documentation

Y0000370

Risperidone for system suitability

Name: Risperidone for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Risperidone, R 64,766

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₂₃H₂₇FN₄O₂

Número de CAS:

106266-06-2

Peso molecular:

410.48

Número MDL:

MFCD00274576

Código UNSPSC:

41116107

ID de la sustancia en PubChem:

329830925

NACRES:

NA.24

Productos recomendados

Slide 1 of 10

1 of 10

USP

1604676

Risperidone Related Compounds Mixture

R1000600

Risperidone

Sigma-Aldrich

SML3059

Lacosamide

Sigma-Aldrich

5.08508

Zonisamide

Y0001276

Risperidone impurity K

Supelco

PHR1631

Risperidone

USP

1151855

Curcumin

M1825000

Metoclopramide hydrochloride

I0750000

Isopropyl tetradecanoate

S0460000

Sertaconazole nitrate

grado

pharmaceutical primary standard

familia API

risperidone

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

formato

neat

cadena SMILES

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

Clave InChI

RAPZEAPATHNIPO-UHFFFAOYSA-N

Información sobre el gen

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Risperidone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto

Descripción

Precios

1604676

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

PHR1631

Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogramas

GHS06

Palabra de señalización

Danger

Frases de peligro

H301

Consejos de prudencia

P301 + P330 + P331 + P310

Clasificaciones de peligro

Acute Tox. 3 Oral

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.

Vina M Goghari et al.

Schizophrenia research, 149(1-3), 149-155 (2013-07-09)

Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study

Comparative study of the complex forming ability and enantioselectivity of cyclodextrin polymers by CE and 1H NMR.

Cécile Danel et al.

Carbohydrate polymers, 92(2), 2282-2292 (2013-02-13)

The interactions between nine drugs (baclofen, bupivacaine, chlorpheniramine, ketoconazole, paliperidone, promethazine, propranolol, risperidone and verapamil) and six cyclodextrins (α-CD, β-CD, γ-CD, HP-β-CD, HP-γ-CD and Me-β-CD) or six polymers of cyclodextrins (polyα-CD, polyβ-CD, polyγ-CD, polyHP-β-CD, polyHP-γ-CD and polyMe-β-CD) were studied by

Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.

Yvonne Freund-Levi et al.

Dementia and geriatric cognitive disorders, 38(3-4), 234-244 (2014-06-28)

To examine the effects of galantamine and risperidone on agitation in patients with dementia. A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized

PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.

Christian Spang Pedersen et al.

Behavioural brain research, 273, 63-72 (2014-07-30)

Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive

Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity.

Jérôme A J Becker et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)

The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico